Type 2 Diabetes Connect
  • Saved

made a Post

4yr
What would be your treatment step to get patient at goal?

56-year old female with type 2 diabetes, BMI of 30 kg/m2 and no major comorbidities, has been on metformin and a sulfonylurea at their highest tolerated doses. Four months ago, her previous physician added a high dose of a DPP-IV inhibitor to help get her to goal of 7%. The treatment regimen brought the A1C to 7.6%. The patient is seeking a second opinion.

Would you consider switching any medications or adding on? Please list what would be your preferred options.

Show More Comments

  • Saved

made a Post

4yr
What would be your treatment step to get patient at goal?

56-year old female with type 2 diabetes, BMI of 30 kg/m2 and no major comorbidities, has been on metformin and a sulfonylurea at their highest tolerated doses. Four months ago, her previous physician added a high dose of a DPP-IV inhibitor to help get her to goal of 7%. The treatment regimen brought the A1C to 7.6%. The patient is seeking a second opinion.



Would you consider switching any medications or adding on? Please list what would be your preferred options.


Show More Comments

  • Saved

4yr

Heterogenicity of diabetes as a risk factor for all-cause mortality after acute myocardial infarction: age and sex impact

Source : https://doi.org/10.1016/j.diabres.2021.109117



Conclusions: The study implies heterogeneity in the impact of T2DM on mortality of post-AMI patients, being greater among young patients, particularly females, and no significant impact in octogenarians. That implies that young women with T2DM should have advanced measures for early detection of coronary artery disease and tight control of...

  • Saved

4yr
Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early-phase study - PubMed

Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early-phase study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34605142/

Aims: To compare the pharmacokinetics (PK), glucodynamics (GD) and tolerability following single and multiple daily subcutaneous doses of ultra rapid lispro (URLi) and Humalog® in patients with type 2 diabetes...



Conclusions: URLi demonstrated accelerated insulin lispro absorption and greater postprandial glucose reduction at different meal-to-dose timings compared with Humalog and was well tolerated in patients with T2D.

  • Saved

4yr

Females with type 2 diabetes are at higher risk for accelerated cognitive decline than males: CAROLINA-COGNITION study

Source : https://doi.org/10.1016/j.numecd.2021.10.013



Conclusion: Females with T2D had a higher risk of ACD compared to males. This was partly explained by depressive symptoms. After evaluation of vascular and diabetes-related risk factors, complications and treatment, a major share of the higher risk of ACD in females remained unexplained. Our results highlight the need for further research on...